TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 35, 2010, Pages 15535-15540

  Yao, Zhan ^a   Fenoglio, Silvia ^a   Gao, Ding Cheng ^b   Camiolo, Matthew ^a   Stiles, Brendon ^b   Lindsted, Trine ^a   Schlederer, Michaela ^c   Johns, Chris ^a   Altorki, Nasser ^b   Mittal, Vivek ^a,b   Kenner, Lukas ^c   Sordella, Raffaella ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Epidermal growth factor receptor; Nonsmall cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MESODERM; MICE; MICE, NUDE; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSFORMING GROWTH FACTOR BETA;

EID: 77957273623     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1009472107     Document Type: Article

References (19)

1. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139. (Pubitemid 38637993)
2. Maemondo M, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388.
3. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311.
4. Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
5. Wakeling AE, et al. (2002) ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-5754.
6. Sequist LV, Bell DW, Lynch TJ, Haber DA (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-595.
7. Engelman JA, Jänne PA (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14:2895-2899.
8. Engelman JA, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043.
9. Gao SP, et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117:3846-3856.
10. Gandhi J, et al. (2009) Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE 4:e4576.
11. Eramo A, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504-514. (Pubitemid 351267301)
12. Lopez-Novoa JM, Nieto MA (2009) Inflammation and EMT: An alliance towards organ fibrosis and cancer progression. EMBO Mol Med 1:303-314.
13. Vasunia KB, Miller ML, Andringa S, Baxter CS (1994) Induction of interleukin-6 in the epidermis of mice in response to tumor-promoting agents. Carcinogenesis 15:1723-1727.
14. Yamaguchi T, et al. (1998) Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol 28:740-744.
15. Catlett-Falcone R, et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 105-115.
16. Haga S, et al. (2003) Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 112:989-998.
17. Thomson S, et al. (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65:9455-9462.
18. Yauch RL, et al. (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11:8686-8698.
19. Barr S, et al. (2008) Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 25:685-693.